Lercanidipine Clonmel (Lercanidipine Hydrochloride)

Lercanidipine blocks L‑type calcium channels in arterial smooth muscle, preventing calcium entry that triggers contraction. This selective inhibition causes vasodilation, lowers peripheral vascular resistance, and consequently reduces systemic blood pressure without markedly affecting heart rate.

The dose of Lercanidipine Clonmel is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant therapies. The prescriber determines the appropriate starting dose and any subsequent adjustments.

Safety data for Lercanidipine in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Lercanidipine and amlodipine belong to the dihydropyridine class of calcium‑channel blockers and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may be associated with a lower incidence of peripheral edema, while amlodipine is more widely studied and available in fixed‑dose combinations.

Store Lercanidipine tablets at room temperature, below 25 °C, in the original container. Protect the product from moisture, direct sunlight and excessive heat to maintain its stability and potency throughout its shelf life.

Lercanidipine is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the regimen without medical advice.

Serious adverse reactions, although rare, include angioedema, severe hypotension, myocardial infarction, hepatic dysfunction, Stevens‑Johnson syndrome, and atrioventricular block. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden faintness, chest pain, or any signs of severe allergic reaction.

Lercanidipine is contraindicated in individuals with known hypersensitivity to the drug or any component of the formulation, patients with severe hypotension, cardiogenic shock, or unstable angina. Caution is also advised for patients with significant hepatic impairment or those taking interacting medications.